Valiant Organics Grants 19,500 Employee Stock Options Under ESOP Scheme 2022

Valiant Organics Limited's Nomination and Remuneration Committee (NRC) of the Board of Directors convened on Saturday, May 16, 2026, and approved the grant of 19,500 (Nineteen Thousand Five Hundred) employee stock options to eligible employees under the Valiant Employees Stock Option Plan 2022 ("ESOP Scheme"). The grant has been made in compliance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company disclosed this development to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Details of the ESOP Grant

The following table summarises the key parameters of the stock option grant as disclosed in Annexure-I filed with the exchanges:

Parameter: Details Total Options Granted: 19,500 Total Equity Shares Covered: 19,500 Exercise Price: Rs. 10/- per option Face Value per Share: Rs. 10/- each Conversion Ratio: 1 option = 1 equity share Exercise Period: Within 3 years from date of vesting Options Exercised: Nil Options Lapsed: Nil Money Realised by Exercise: Nil

Vesting Structure

The 19,500 options granted carry a structured vesting schedule as determined by the NRC. Of the total options granted, 15,000 options shall vest upon completion of a minimum vesting period of 1 year. The remaining options are subject to vesting upon achievement of specified performance criteria, as determined by the NRC in accordance with the applicable ESOP Scheme.

Once vested, each option entitles the holder to acquire one equity share of Valiant Organics upon payment of the exercise price. The exercise price shall in no event be less than the face value of the share, as prescribed under the scheme terms.

Scheme Administration and Compliance

The ESOP Scheme is administered by the NRC of the Board of Directors. The grant of options is based on eligibility criteria as defined under the scheme. The NRC determines the exercise price subject to conformity with applicable accounting policies. The scheme is in terms of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Key highlights of the scheme's governance framework include:

The NRC oversees administration and eligibility determination

Exercise price is set at Rs. 10/- per option, consistent with the face value

Diluted earnings per share pursuant to the issue of equity shares on exercise of options is not yet applicable, as options are yet to be exercised

No subsequent changes, cancellations, or variations to option terms have been reported

The intimation was signed by Kaustubh Kulkarni, Company Secretary (ICSI M. No: A52980), on behalf of Valiant Organics Limited.

Valiant Organics Limited has reported its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company returned to profitability in FY26, recording a net profit of ₹3,435.56 lakh compared to a net loss of ₹299.84 lakh in the previous fiscal year. This turnaround was supported by revenue from operations, which increased to ₹73,838.31 lakh from ₹71,876.18 lakh in FY25.

For the quarter ended March 31, 2026, the net profit stood at ₹1,511.74 lakh, a significant rise from ₹395.62 lakh in the corresponding quarter of the previous year. Revenue for the quarter reached ₹21,770.02 lakh, up from ₹20,381.19 lakh in the same period last year. The Board identified the Pharma Business as an additional reportable segment alongside the existing Specialty Chemicals segment, in accordance with Ind AS 108.

Financial Performance

Total income for the year ended March 31, 2026, grew to ₹74,529.79 lakh from ₹72,701.54 lakh in the prior year. Total expenses decreased to ₹70,795.98 lakh from ₹72,460.55 lakh in the previous year. Profit before tax improved substantially to ₹4,305.89 lakh from ₹240.99 lakh. The statutory auditors, M/s. Gokhale & Sathe, issued an audit report with an un-modified opinion for the financial year ended March 31, 2026.

Standalone Financial Results

The table below summarises the key standalone financial metrics for the year ended March 31, 2026:

Particulars Year Ended 31-Mar-2026 (₹ in Lakhs) Year Ended 31-Mar-2025 (₹ in Lakhs) Revenue from Operations 73,838.31 71,876.18 Total Income 74,529.79 72,701.54 Total Expenses 70,795.98 72,460.55 Profit Before Tax 4,305.89 240.99 Net Profit / (Loss) 3,435.56 (299.84) Basic EPS (₹) 12.27 (1.09)

Segment Reporting

Based on internal reports, the Board approved the identification of the Pharma Business as an additional reportable segment. For the year ended March 31, 2026, the Specialty Chemical Division reported revenue of ₹57,481.94 lakh, while the newly identified Pharma Division reported revenue of ₹16,356.38 lakh. The company also received ₹852.76 lakhs towards a fire insurance claim settlement during the year, with ₹572.08 lakhs recognised under exceptional items.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.